These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 1919296)

  • 21. [The effect of exogenous interferon on the in vitro production of alpha- and gamma-interferon by the lymphocytes of patients with respiratory papillomatosis].
    Grigorian SS; Pritsker AD; Onufrieva EK; Chireshkin DG; Ershov FI
    Vopr Virusol; 1991; 36(5):407-9. PubMed ID: 1803775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Children and partners of patients with recurrent respiratory papillomatosis have no evidence of the disease during long-term observation.
    Gerein V; Soldatski IL; Babkina N; Onufrieva EK; Barysik N; Pfister H
    Int J Pediatr Otorhinolaryngol; 2006 Dec; 70(12):2061-6. PubMed ID: 16945430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management.
    Roffi L; Mels GC; Antonelli G; Bellati G; Panizzuti F; Piperno A; Pozzi M; Ravizza D; Angeli G; Dianzani F
    Hepatology; 1995 Mar; 21(3):645-9. PubMed ID: 7875661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells.
    Abdul-Ahad AK; Galazka AR; Revel M; Biffoni M; Borden EC
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):27-32. PubMed ID: 9287241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up.
    Angelico M; Gandin C; Pescarmona E; Rapicetta M; Del Vecchio C; Bini A; Spada E; Baroni CD; Capocaccia L
    Am J Gastroenterol; 1995 Feb; 90(2):263-9. PubMed ID: 7847298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for an antiviral effect and interferon neutralizing capacity in human sera; variability and implications for HIV infection.
    Fall LS; Chams V; Le Coq H; Fouchard M; M'Bika JP; Gringeri A; Santagostino E; Bizzini B
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):409-16. PubMed ID: 7580835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The predictive value of serum interleukins in recurrent respiratory papillomatosis: a preliminary study.
    Snowden RT; Thompson J; Horwitz E; Stocks RM
    Laryngoscope; 2001 Mar; 111(3):404-8. PubMed ID: 11224768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection and characterization of antibodies against recombinant human erythropoietin by RIPA, ELISA and neutralization assay in patients with renal anemia.
    Gross J; Moller R; Bischoff S; Canaan-Kühl S; Fromme M; Henke W
    J Immunol Methods; 2008 Jul; 336(2):152-8. PubMed ID: 18501920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a.
    Itri LM; Sherman MI; Palleroni AV; Evans LM; Tran LL; Campion M; Chizzonite R
    J Interferon Res; 1989 Sep; 9 Suppl 1():S9-15. PubMed ID: 2681444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors.
    Oberg K; Alm G
    Biotherapy; 1997; 10(1):1-5. PubMed ID: 9261544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Assessment of the formation of antibodies to interferon in patients with juvenile respiratory papillomatosis on interferon therapy].
    Kol'tsov VD; Chireshkin DG; Onufrieva EK; Nurmukhametov RKh; Malinovskaia VV; Ershov FI
    Vestn Otorinolaringol; 1996; (4):25-7. PubMed ID: 8966873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to recombinant alpha interferon therapy in idiopathic mixed cryoglobulinemia: reinduction of remission by natural alpha interferon both in antibody-positive and -negative patients.
    Casato M; Antonelli G; Maggi F; Pucillo LP; Di Lullo L; Leoni M; Currenti M; Dianzani F; Bonomo L
    J Biol Regul Homeost Agents; 1994; 8(2):56-9. PubMed ID: 7863814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IFN-alpha antibodies in patients with age-related macular degeneration treated with recombinant human IFN-alpha2a.
    Ross C; Engler CB; Sander B; Bendtzen K
    J Interferon Cytokine Res; 2002 Apr; 22(4):421-6. PubMed ID: 12034024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients.
    Dianzani F; Antonelli G; Amicucci P; Cefaro A; Pintus C
    J Interferon Res; 1989 Sep; 9 Suppl 1():S33-6. PubMed ID: 2681442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Side effects and toxicity of interferon in the treatment of recurrent respiratory papillomatosis.
    Crockett DM; McCabe BF; Lusk RP; Mixon JH
    Ann Otol Rhinol Laryngol; 1987; 96(5):601-7. PubMed ID: 3674659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit.
    Grossberg SE; Kawade Y; Kohase M; Klein JP
    J Interferon Cytokine Res; 2001 Sep; 21(9):743-55. PubMed ID: 11576468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absence of neutralizing antibodies to interferon in condyloma acuminata and cancer patients treated with natural human leukocyte interferon.
    Liao MJ; Axelrod HR; Kuchler M; Yip YK; Kirkbright E; Testa D
    J Infect Dis; 1992 Apr; 165(4):757-60. PubMed ID: 1552208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of patients with respiratory papillomatosis: experience analysis].
    Zegner VG; Ashurov ZM; Sloeva AI
    Vestn Ross Akad Med Nauk; 2005; (5):25-8. PubMed ID: 15960200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunocompetency in children with recurrent respiratory papillomatosis: prospective study.
    Stern Y; Felipovich A; Cotton RT; Segal K
    Ann Otol Rhinol Laryngol; 2007 Mar; 116(3):169-71. PubMed ID: 17419519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.